Dermira Inc (DERM) was Reiterated by Needham to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 42 from a previous price target of $38 . Needham advised their investors in a research report released on May 11, 2016.
Dermira Inc opened for trading at $29 and hit $29.4399 on the upside on Tuesday, eventually ending the session at $28.69, with a gain of 17.29% or 4.23 points. The heightened volatility saw the trading volume jump to 14,50,384 shares. Company has a market cap of $860 M.
In a different news, on May 3, 2016, Eugene A Bauer (Chief Medical Officer) sold 2,500 shares at $25.09 per share price. According to the SEC, on May 3, 2016, Thomas G Wiggans (CEO & Chairman of the Board) sold 9,000 shares at $25.11 per share price.
Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.